Factors influencing serum ca125ii levels in healthy postmenopausal women

Cancer Epidemiology Biomarkers and Prevention

Volumn 10, Issue 5, 2001, Pages 489-493

  Pauler, Donna K ^a   Menon, Usha ^c   McIntosh, Martin ^a   Symecko, Heather L ^b   Skates, Steven J ^b   Jacobs, Ian J ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c ROYAL LONDON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CAFFEINE; ORAL CONTRACEPTIVE AGENT; TALC;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER SCREENING; CORRELATION FUNCTION; FEMALE; FOLLOW UP; HUMAN; HYSTERECTOMY; IMMUNOASSAY; MAJOR CLINICAL STUDY; MEASUREMENT; OVARIECTOMY; OVARY CANCER; OVARY CYST; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; RACE DIFFERENCE; SMOKING;

AGE DISTRIBUTION; AGED; BIOLOGICAL MARKERS; CA-125 ANTIGEN; COHORT STUDIES; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; MASS SCREENING; MIDDLE AGED; OVARIAN NEOPLASMS; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PROBABILITY; REFERENCE VALUES; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 0034921718     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Preoperative tumor marker CA125 levels in relation to epithelial ovarian cancer stage
2. Tumor markers in ovarian malignancies
3. Early detection of familial ovarian cancer
4. Clinical value of a new serum tumor marker, CA125II, in gynecologic disease: Comparison with CA125
5. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers
6. Multimodal approach to screening for ovarian cancer
7. Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women
8. Prevalence screening for ovarian cancer in postmenopausal women by CA125 measurement and ultrasonography
9. Risk of diagnosis of ovarian cancer after raised serum CA125 concentration: A prospective cohort study
10. Screening for ovarian cancer: A pilot randomized control trial
11. A comparison of national cancer registry and direct follow-up in the ascertainment of ovarian cancer
12. Random effect models for longitudinal data
13. Estimating the dimension of a model
14. The Schwarz criterion and related methods for normal linear models
15. Factors influencing serum CA125 levels in normal women
16. Serum CA125 levels in a group of nonhospitalized women: Relevance for the early detection of ovarian cancer
17. The CA125 tumor-associated antigen: A review of the literature
18. CA125 antigen levels in obstetric and gynecologic patients
19. CA125 levels in menopausal women
20. Evaluation of serum CA125 valves in healthy individuals and pregnant women
21. CA125 antigen in human amniotic fluid and fetal membranes
22. The distribution of CA125 in the reproductive tract of pregnant and nonpregnant women
23. Increased serum CA125 levels during the first trimester of pregnancy
24. Determination of a normal level of serum CA125 in postmenopausal women as a tool for preoperative evaluation and postoperative surveillance of endometrial carcinoma
25. A prospective randomized controlled study comparing the morphological and biochemical responses of the endometrium to two different forms of "period free" hormone replacement therapy
26. Use of a second-generation CA125 assay in gynecologic patients
27. CA19-9 and CA125 levels in the sera of normal blood donors in relation to smoking history
28. What is normal CA125 level?
29. Prospective evaluation of serum CA125 levels in a normal population, Phase I: The specificities of single and serial determinations in testing for ovarian cancer
30. An evaluation of CA125 levels in 291 normal postmenopausal and 20 endometrial adenocarcinoma-bearing women before and after surgery
31. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA125) associated with human epithelial ovarian carcinomas
32. Comparison of seven immunoassays for the quantification of CA125 antigen in serum